콘텐츠로 건너뛰기
Merck
모든 사진(1)

Key Documents

View All Documentation

P0310000

Penicillamine

European Pharmacopoeia (EP) Reference Standard

동의어(들):

D-Penicillamine, 3,3-Dimethyl-D-cysteine, 3-Mercapto-D-valine, D-(−)-2-Amino-3-mercapto-3-methylbutanoic acid

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

Linear Formula:
(CH3)2C(SH)CH(NH2)CO2H
CAS Number:
52-67-5
Molecular Weight:
149.21
Beilstein:
1722375
MDL number:
MFCD00064302
UNSPSC 코드:
41116107
PubChem Substance ID:
329820030
NACRES:
NA.24

Grade

pharmaceutical primary standard

API family

penicillamine

제조업체/상표

EDQM

mp

210 °C (dec.) (lit.)

응용 분야

pharmaceutical (small molecule)

형식

neat

저장 온도

2-8°C

SMILES string

CC(C)(S)[C@@H](N)C(O)=O

InChI

1S/C5H11NO2S/c1-5(2,9)3(6)4(7)8/h3,9H,6H2,1-2H3,(H,7,8)/t3-/m0/s1

InChI key

VVNCNSJFMMFHPL-VKHMYHEASA-N

유사한 제품을 찾으십니까? 방문 제품 비교 안내

일반 설명

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

애플리케이션

Penicillamine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

포장

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

기타 정보

Sales restrictions may apply.

픽토그램

Health hazard
GHS08

신호어

Warning

유해 및 위험 성명서

H361d

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

죄송합니다. 지금은 이 제품에 대한 COA이(가) 온라인에서 제공되지 않습니다.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

A Boehler et al.
The European respiratory journal, 9(6), 1317-1319 (1996-06-01)
D-penicillamine-associated bronchiolitis obliterans (BO) is a rare but well-known pulmonary complication in patients with rheumatoid arthritis or progressive systemic sclerosis. It has been assumed that in most, if not all cases, BO is a complication of the underlying disease rather
Y Gong et al.
Alimentary pharmacology & therapeutics, 24(11-12), 1535-1544 (2007-01-09)
D-Penicillamine is used for patients with primary biliary cirrhosis due to its ability to decrease hepatic copper and modulate the immune response. The results on effects of D--penicillamine in randomized-clinical trials of primary biliary cirrhosis patients are inconsistent. To systematically
J Karpinski et al.
American journal of nephrology, 17(6), 528-532 (1997-01-01)
Therapeutic use of D-penicillamine has been associated with a range of adverse effects. We present a patient with scleroderma, treated with D-penicillamine for 5 years, who developed severe renal failure due to rapidly progressive glomerulonephritis with both crescents and subepithelial
S L Klingenberg et al.
The Cochrane database of systematic reviews, (1)(1), CD004182-CD004182 (2006-01-27)
Primary sclerosing cholangitis is a cholestatic disease. D-penicillamine is suggested as a treatment option due to its copper reducing and immunomodulatory potential. To evaluate the beneficial and harmful effects of D-penicillamine for patients with primary sclerosing cholangitis. Eligible trials were
[D-penicillamine nephropathy].
I Ohno
Ryoikibetsu shokogun shirizu, (16 Pt 1)(16 Pt 1), 523-525 (1997-01-01)
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.